Yescarta (axicabtagene ciloleucel)
Relapsed/Refractory Large B-Cell Lymphoma (multiple types)
ApprovedActive
Key Facts
Indication
Relapsed/Refractory Large B-Cell Lymphoma (multiple types)
Phase
Approved
Status
Active
Company
About Kite Pharma
Kite Pharma is a global leader in cell therapy, operating as an independent subsidiary of Gilead Sciences. The company has commercialized two autologous CAR T-cell therapies, Yescarta and Tecartus, for various B-cell malignancies, establishing a significant presence in the immuno-oncology market. With a deep pipeline exploring next-generation cell therapies and manufacturing innovations, Kite aims to extend its curative potential to more cancer types. Its business model is fully integrated, encompassing R&D, manufacturing, and commercialization of its proprietary therapeutics.
View full company profile